Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 4, 2004 J. Graham	Sanofi's Aggressive for Aventis The drug company wants larger rival Aventis any way it can get it.
BusinessWeek February 9, 2004 Kerry Cappell	This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
BusinessWeek March 29, 2004 Kerry Capell	A Drug Behemoth In The Making? Novartis plus Aventis would create the world's No. 2 drugmaker, unless politics get in the way
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
BusinessWeek December 27, 2004 Carol Matlack	Growing Pains At Sanofi The pipeline looks good at the world's No. 3 drugmaker -- but investors are waiting for cost cuts.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
BusinessWeek November 22, 2004	A Boost For France's Sanofi-Aventis The French government's goal of creating a national pharmaceutical champion got a big boost when Paris-based Sanofi-Aventis released promising data on an experimental drug that helps people lose weight and stop smoking.
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool June 7, 2004 Brian Gorman	Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.
BusinessWeek February 2, 2004 Kerry Capell	Aventis: Investors Await Their Reward Debt is down, margins are up. So why is the drugmaker's stock lagging its peers?
BusinessWeek November 29, 2004 John Rossant	France's Industrial Power Trip Paris can't stop interfering with the economy -- and that's bad news for Europe.
The Motley Fool October 27, 2010 Selena Maranjian	When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool June 17, 2004 Dave Marino-Nachison	Jones, Maxwell Negotiate Hostile and/or unsolicited buyout offers are invariably exciting to watch, but can be nerve-racking if you've got something invested.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
BusinessWeek May 10, 2004 John Rossant	The Pernicious Rise Of "Core Europe" Germany and France are building a bloc to preserve their political and economic influence.
The Motley Fool June 18, 2010 Brian Orelli	Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
BusinessWeek April 12, 2004 John Rossant	Europe Is Playing With Fire Just about everywhere you look in Europe, the protectionist rhetoric is rising. Keeping national control over key companies and industries is seen as a way to make sure jobs don't evaporate.
BusinessWeek March 22, 2004 David Fairlamb	Europe: Deals Are Back In Season The strong euro and healthy profits have CEOs in a mood to go shopping
BusinessWeek May 31, 2004	A New Twist In The Alstom Rescue France's plan to rescue the engineering group is straining relations with Germany.
Pharmaceutical Executive July 1, 2009	French Revolution Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning... and rolling.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
The Motley Fool August 30, 2010 Brian Orelli	Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
Chemistry World September 26, 2012 Andrew Turley	Sanofi to cut 900 jobs in France It is not planning to move or close any of its industrial sites in France, but the future of the R&D site in Toulouse, which employs over 600 people, remains uncertain.
The Motley Fool February 10, 2009 Robert Steyer	Rx for a Drug Deal? Will circumstance and psychology prod Sanofi-Aventis into a big acquisition?
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool August 30, 2010 Brian Orelli	It's a Blockbuster ... Maybe On the surface, sanofi-aventis' oral multiple sclerosis drug teriflunomide looks like a hit. But below the surface?
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool June 20, 2005 Richard Gibbons	Think Like a Dealmaker Acquisitions can be great for investors. Here's how to identify acquisition targets before deals are announced.
BusinessWeek December 9, 2009 Kelley & Torsoli	Major Surgery at Sanofi CEO Chris Viehbacher has been on a buying spree and a charm offensive, both of which are reversing the drugmaker's losing streak.
Chemistry World January 3, 2014 Ben Valsler	Sanofi suffers multiple sclerosis setback French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration rejected its multiple sclerosis drug Lemtrada (alemtuzumab).
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool June 6, 2008 Brian Lawler	Sorry, Sanofi: More Bad News The pharmaceutical's top drug prospect is linked to more side effects.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool June 23, 2008 Brian Lawler	Sanofi Goes East to Find Growth Sanofi-Aventis announces that it has outbid a rival for Czech generic-drug maker Zentiva.
The Motley Fool September 24, 2008 Brian Lawler	Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva.